Trial Profile
A real world study evaluating efficacy and safety of Glatiramer-acetate in patients with multiple sclerosis in Spain
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2018
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis